Quick Answer
RenovoRx, Inc. reported Net Income of -$11.17 million for fiscal year 2025.
RenovoRx, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$11.17M | -26.7% |
| 2024 | -$8.81M | +13.9% |
| 2023 | -$10.23M | -3.5% |
| 2022 | -$9.89M | -56.4% |
| 2021 | -$6.32M | -66.5% |
| 2020 | -$3.80M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.91M | -17.8% | -0.6% |
| June 30, 2025 | -$2.90M | -21.2% | -19.6% |
| March 31, 2025 | -$2.42M | -124.9% | +2.1% |
| September 30, 2024 | -$2.47M | -73.9% | -3.4% |
| June 30, 2024 | -$2.39M | -2.7% | -122.0% |
| March 31, 2024 | -$1.08M | +67.0% | +24.3% |
| September 30, 2023 | -$1.42M | +33.5% | +38.9% |
| June 30, 2023 | -$2.33M | +10.3% | +28.6% |
- RenovoRx, Inc. showed a decrease of -26.7% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, RenovoRx, Inc.’s net income has declined by 194.0% (from -$3.80 million to -$11.17 million).
- The most recent figure is from RenovoRx, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: